vs
Side-by-side financial comparison of MESA LABORATORIES INC (MLAB) and UMH PROPERTIES, INC. (UMH). Click either name above to swap in a different company.
UMH PROPERTIES, INC. is the larger business by last-quarter revenue ($67.0M vs $65.1M, roughly 1.0× MESA LABORATORIES INC). UMH PROPERTIES, INC. runs the higher net margin — 6.8% vs 5.6%, a 1.3% gap on every dollar of revenue. On growth, UMH PROPERTIES, INC. posted the faster year-over-year revenue change (8.2% vs 3.6%). Over the past eight quarters, UMH PROPERTIES, INC.'s revenue compounded faster (7.8% CAGR vs 5.1%).
Mesa Laboratories Inc. develops, manufactures and sells professional quality control, calibration and monitoring instruments as well as related supporting services. Its core offerings cater to healthcare, pharmaceutical, food and beverage, industrial hygiene and environmental testing markets, helping global clients meet regulatory compliance and operational safety requirements.
UMH Properties, Inc. is a public equity real estate investment trust (REIT) that owns and operates a portfolio of 135 manufactured home communities with approximately 25,700 developed homesites. These communities are located in 12 states: New Jersey, New York, Ohio, Pennsylvania, Tennessee, Indiana, Michigan, Maryland, Alabama, South Carolina, Georgia, and Florida. UMH also owns and operates two communities in Florida through its joint venture with Nuveen Real Estate.
MLAB vs UMH — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $65.1M | $67.0M |
| Net Profit | $3.6M | $4.6M |
| Gross Margin | 64.2% | — |
| Operating Margin | 12.2% | — |
| Net Margin | 5.6% | 6.8% |
| Revenue YoY | 3.6% | 8.2% |
| Net Profit YoY | 316.6% | -8.1% |
| EPS (diluted) | $0.65 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $65.1M | $67.0M | ||
| Q3 25 | $60.7M | $66.9M | ||
| Q2 25 | $59.5M | $66.6M | ||
| Q1 25 | $62.1M | $61.2M | ||
| Q4 24 | $62.8M | $61.9M | ||
| Q3 24 | $57.8M | $60.7M | ||
| Q2 24 | $58.2M | $60.3M | ||
| Q1 24 | $58.9M | $57.7M |
| Q4 25 | $3.6M | $4.6M | ||
| Q3 25 | $2.5M | $9.3M | ||
| Q2 25 | $4.7M | $7.6M | ||
| Q1 25 | $-7.1M | $4.8M | ||
| Q4 24 | $-1.7M | $5.0M | ||
| Q3 24 | $3.4M | $12.9M | ||
| Q2 24 | $3.4M | $5.2M | ||
| Q1 24 | $-254.6M | $-1.6M |
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — | ||
| Q1 24 | 62.1% | — |
| Q4 25 | 12.2% | — | ||
| Q3 25 | 7.8% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 9.2% | — | ||
| Q3 24 | 6.1% | — | ||
| Q2 24 | 9.6% | — | ||
| Q1 24 | -460.6% | — |
| Q4 25 | 5.6% | 6.8% | ||
| Q3 25 | 4.1% | 13.9% | ||
| Q2 25 | 8.0% | 11.4% | ||
| Q1 25 | -11.4% | 7.9% | ||
| Q4 24 | -2.7% | 8.0% | ||
| Q3 24 | 5.9% | 21.3% | ||
| Q2 24 | 5.8% | 8.6% | ||
| Q1 24 | -432.2% | -2.8% |
| Q4 25 | $0.65 | $-0.01 | ||
| Q3 25 | $0.45 | $0.05 | ||
| Q2 25 | $0.85 | $0.03 | ||
| Q1 25 | $-1.30 | $0.00 | ||
| Q4 24 | $-0.31 | $0.00 | ||
| Q3 24 | $0.63 | $0.11 | ||
| Q2 24 | $0.62 | $0.01 | ||
| Q1 24 | $-47.26 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $29.0M | $72.1M |
| Total DebtLower is stronger | $68.4M | — |
| Stockholders' EquityBook value | $186.7M | $905.5M |
| Total Assets | $434.8M | $1.7B |
| Debt / EquityLower = less leverage | 0.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.0M | $72.1M | ||
| Q3 25 | $20.4M | $34.1M | ||
| Q2 25 | $21.3M | $79.2M | ||
| Q1 25 | $27.3M | $35.2M | ||
| Q4 24 | $27.3M | $99.7M | ||
| Q3 24 | $24.3M | $66.7M | ||
| Q2 24 | $28.5M | $39.5M | ||
| Q1 24 | $28.2M | $39.9M |
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $186.7M | $905.5M | ||
| Q3 25 | $178.5M | $924.7M | ||
| Q2 25 | $172.5M | $932.0M | ||
| Q1 25 | $159.8M | $912.4M | ||
| Q4 24 | $155.2M | $914.0M | ||
| Q3 24 | $161.5M | $856.5M | ||
| Q2 24 | $150.7M | $742.0M | ||
| Q1 24 | $145.4M | $715.1M |
| Q4 25 | $434.8M | $1.7B | ||
| Q3 25 | $430.4M | $1.6B | ||
| Q2 25 | $435.7M | $1.6B | ||
| Q1 25 | $433.3M | $1.5B | ||
| Q4 24 | $433.3M | $1.6B | ||
| Q3 24 | $454.1M | $1.5B | ||
| Q2 24 | $440.4M | $1.4B | ||
| Q1 24 | $446.8M | $1.4B |
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.8M | $82.0M |
| Free Cash FlowOCF − Capex | $18.0M | — |
| FCF MarginFCF / Revenue | 27.7% | — |
| Capex IntensityCapex / Revenue | 1.1% | — |
| Cash ConversionOCF / Net Profit | 5.17× | 17.92× |
| TTM Free Cash FlowTrailing 4 quarters | $37.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.8M | $82.0M | ||
| Q3 25 | $8.2M | $23.4M | ||
| Q2 25 | $1.9M | $24.4M | ||
| Q1 25 | $12.7M | $12.8M | ||
| Q4 24 | $18.1M | $81.6M | ||
| Q3 24 | $5.3M | $16.7M | ||
| Q2 24 | $10.7M | $18.6M | ||
| Q1 24 | $12.9M | $19.0M |
| Q4 25 | $18.0M | — | ||
| Q3 25 | $7.1M | — | ||
| Q2 25 | $884.0K | — | ||
| Q1 25 | $11.9M | — | ||
| Q4 24 | $17.3M | — | ||
| Q3 24 | $3.5M | — | ||
| Q2 24 | $9.9M | — | ||
| Q1 24 | $12.3M | — |
| Q4 25 | 27.7% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 19.2% | — | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | 16.9% | — | ||
| Q1 24 | 21.0% | — |
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | 5.17× | 17.92× | ||
| Q3 25 | 3.32× | 2.53× | ||
| Q2 25 | 0.40× | 3.21× | ||
| Q1 25 | — | 2.66× | ||
| Q4 24 | — | 16.39× | ||
| Q3 24 | 1.54× | 1.30× | ||
| Q2 24 | 3.17× | 3.58× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
UMH
Segment breakdown not available.
